81 results about "Oa osteoarthritis" patented technology

The invention discloses an application of tiopronin wrapped by ROS (reactive oxygen species) response hydrogel in preparation of a medicine for treating osteoarthritis. The ROS response hydrogel is prepared from the following components: tiopronin; the compound group of lecithin and ketal thiol (TK) is TK-NH22, 2 '-(propane-2, 2-diyl bis (sulfanilamide diyl)) diethylamine (sulfanediyl), and the compound group of lecithin and ketal thiol (TK) is TK-NH22, 2'-(propane-2, 2-diyl bis (sulfanilamide diyl)); 12 wt% of methyl cellulose, Na2HPO4. 12H2O and xylitol; according to the hydrogel, controlled release of tiopronin is achieved through an ROS response group, mitochondrial autophagy is enhanced by up-regulating a Bnip3-Pink1-Parkin signal channel, oxidative stress is inhibited, and the progress of osteoarthritis is delayed; compared with the prior art, the invention has the advantages that: the invention discloses an osteoarthritis treatment medicine with the effects of resisting inflammation, relieving pain and inhibiting cartilage degeneration for the first time, and discloses a knee joint intracavity administration route of tiopronin for the first time. Particularly, the tiopronin targeted activation Bnip3-Pink1-Parkin signal channel provided by the invention has a remarkable effect in the aspect of inhibiting the progress of OA, which proves that the medicine has a strong effect on the treatment of osteoarthritis.

The invention belongs to the technical field of medical treatment, and discloses an osteoarthritis rehabilitation auxiliary device and system, and the device comprises an intelligent vibration treatment module, a pressure sensor and biological feedback module, an intelligent control and APP remote management module, a pressure sensor, an accelerometer, and a myoelectricity sensor. The joint pain is relieved, vibration can stimulate sensory nerves, pain signal transmission is reduced, and the pain degree is reduced. Vibration promotes secretion of joint fluid, friction is reduced, and the range of motion is improved. Low-frequency vibration stimulates the activity of cartilage cells, and cartilage degeneration is slowed down. And a biological feedback system is intelligently regulated and controlled, so that the treatment accuracy is improved. Non-invasive treatment is achieved, and no side effect exists; gastrointestinal discomfort caused by drug treatment or high cost of long-term physical treatment is avoided. Remote monitoring is achieved, compliance is improved, a patient can be treated at home and does not need to see a doctor frequently, and medical cost is reduced.

There is provided a method of diagnosis comprising providing a sample previously isolated from a subject and analysing the sample for presence of a peptide comprising the amino acid sequence N- terminal-KSSTG (SEQ ID NO 1). The diagnosis may be for example diagnosis of a disease is selected from: osteoarthritis, early stage osteoarthritis, moderate osteoarthritis, osteoarthritis associated with risk for chip fractures of the joint or risk for avulsion fractures, severe osteoarthritis, microfractures of the joints, avulsion fractures and chip fractures of the joint.

The invention provides a pharmaceutical composition for bone joints as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition is prepared from the following components in parts by weight: 20 to 2000 parts of N-acetylglucosamine and 10 to 1000 parts of non-denatured type II collagen. In the compound composition of the N-acetylglucosamine and the non-denatured type II collagen, the two core components play a complementary role: the N-acetylglucosamine is focused on promoting synthesis of a cartilage matrix and provides a material basis for cartilage repair; the non-denatured type II collagen reduces damage of autoimmune response to cartilage through immunoregulation, the non-denatured type II collagen and the non-denatured type II collagen have a synergistic effect, the symptoms such as arthralgia and swelling can be relieved, the joint structure can be improved from the double angles of repairing and protecting, and particularly the treatment effect on patients with severe osteoarthritis is remarkably superior to that of a single-component preparation; and an innovative and efficient choice is provided for the treatment of osteoarticular diseases.

A novel PACE4 inhibitor and use thereof in anti-osteoarthritis. A novel PACE4 inhibitory peptide is designed and synthesized, which can effectively inhibit the expression of extracellular PACE4 without affecting normal cells, and is stable in joints and unstable in plasma, so that the PACE4 inhibitory peptide has excellent safety and can be effectively used in the prevention and treatment of OA.

The invention discloses a method for establishing a cat osteoarthritis pain model, which comprises the following steps of: performing experimental research on immunogen, drug concentration, immunization frequency, administration route, injection dosage and the like, and adopting collagen immunogen and 1% carrageenan immunogen as mixed immunogen; a cat is immunized by adopting a two-point injection mode of subcutaneous injection near a shoulder blade and plantar subcutaneous injection, the immunization procedure adopts twice immunization of 0 day and 7 days, a simple and efficient cat osteoarthritis pain model is successfully constructed, the model has obvious joint and claw swelling, a cat claw retraction threshold value is reduced, a TNF-a factor is obviously increased, and the model can be used for researching the pain of the cat osteoarthritis, the pain of the cat osteoarthritis and the pain of the cat osteoarthritis. The method can be used for researching the pathogenesis, pathological change, pain mechanism and OA treatment method of the cat osteoarthritis, and can also be used for evaluating the clinical effect of a novel analgesic drug for the cat osteoarthritis.

Compositions and methods for improving chondrogenesis, or treating osteoarthritis, or treating joint degradation or treating an osteochondral defect in a subject.

The present invention discloses the use of a benzenesulfonamide compound in the preparation of a medicament for preventing and / or treating osteoarthritis. This invention proposes for the first time the use of a benzenesulfonamide compound in a medicament for preventing and / or treating osteoarthritis. Experiments have shown that administration of a benzenesulfonamide compound can significantly improve joint swelling and wear in osteoarthritis mice; at the same time, the benzenesulfonamide compound can significantly reduce cartilage damage and inhibit the progression of joint fibrosis in osteoarthritis mice; in addition, the benzenesulfonamide compound significantly inhibits the expression of inflammation-related markers in the serum of osteoarthritis model mice. The above experiments demonstrate that benzenesulfonamide compounds can improve osteoarthritis and are of great significance for the future development of drugs and the prevention and treatment of such diseases.

The invention discloses a magnetocaloric therapeutic apparatus for osteoarthritis diseases, which comprises a magnetocaloric therapeutic apparatus main body and magnetocaloric massage balls, a motor box is fixedly mounted on the left side of the magnetocaloric therapeutic apparatus main body, a transmission shaft is mounted in the magnetocaloric therapeutic apparatus main body, and a hot compress table is mounted at the top end of the magnetocaloric therapeutic apparatus main body. A treatment seat is arranged at the top end of the magnetic thermal treatment device main body, a position adjusting block is arranged in the magnetic thermal treatment device main body, and a lifting adjusting frame is arranged on the surface of the magnetic thermal treatment device main body. According to the magnetocaloric therapeutic apparatus, the magnetocaloric massage balls emit heat to conduct hot compress on bone joints of a patient, meanwhile, the servo motor rotates to enable the hot compress table to horizontally move back and forth at the top end of the magnetocaloric therapeutic apparatus body, and in this way, the magnetocaloric massage balls can massage the bone joints of legs while conducting hot compress on the patient; the position of the treatment seat can be correspondingly adjusted according to the use requirements of a patient, and when the grip is held and lifted, an upward pulling force can be generated on the patient.

The invention discloses a parasitic loranthus exosome-like nano vesicle and application thereof in preparation of a medicine for treating temporomandibular joint osteoarthritis. The taxillus sutchuenensis exosome-like nano-vesicles are prepared by combining a differential ultracentrifugation method with an ultrafiltration method. Researches show that the taxillus sutchuenensis exosome-like nano-vesicles can treat temporomandibular joint osteoarthritis through the following aspects: 1) an anti-inflammatory function: effectively reducing expression of inflammatory factors; 2) a cartilage degeneration inhibition function: blocking a cartilage matrix degradation pathway, and slowing down cartilage tissue damage; the taxillus sutchuenensis exosome-like nano-vesicles have the advantages that the taxillus sutchuenensis exosome-like nano-vesicles have obvious protection and repair effects on relieving temporal-mandibular joint osteoarthritis related bone and cartilage damage, and accordingly the taxillus sutchuenensis exosome-like nano-vesicles have good application prospects.

The invention discloses a novel PACE4 inhibitor and application of the novel PACE4 inhibitor in resisting osteoarthritis. The novel PACE4 inhibitory peptide designed and synthesized by the invention can effectively inhibit expression of extracellular PACE4 without influencing normal cells, and is stable in joints and unstable in plasma, so that the novel PACE4 inhibitory peptide has excellent safety and can be effectively used for preventing and treating OA.

The present invention relates to a method of screening for osteoarthritis (OA) and rheumatoid arthritis (RA) in a subject suffering from arthritis or suspected of suffering from arthritis and a method of discriminating between OA and rheumatoid arthritis RA comprising determining the level of one or more glycosaminoglycan (GAG) properties according to the invention in a sample of bodily fluid. The invention also provides methods for monitoring OA or RA progression in a subject suffering from arthritis.

The present invention provides compositions and methods for treating joint disorders characterized by inflammatory components. In certain aspects, the compositions and methods are useful for preventing the progression of and treating osteoarthritis and other arthritis in mammalian joints.

The invention discloses an application of mPGES-2 as a target spot in developing, screening or preparing a medicine for preventing and / or treating osteoarthritis. The invention proposes that mPGES-2 is a drug target of osteoarthritis for the first time. Experiments show that mPGES-2 knockout can significantly relieve joint swelling, protect cartilage wear, improve bone metabolism abnormality and inhibit release of inflammatory factors; meanwhile, the mPGES-2 has a remarkable effect on improving osteoarthritis, can be used as a target spot for treating osteoarthritis, and is of great significance to development, prevention and treatment of drugs for the diseases in the future.

The present invention demonstrates that isosakurabin can inhibit the formation and function of osteoclasts in vitro, protect the bone microstructure of the subchondral bone in mice with osteoarthritis (OA), reduce articular cartilage degeneration in OA mice, inhibit the formation of abnormal blood vessels in the subchondral bone marrow cavity during OA progression, and alleviate joint pain induced by abnormal osteoclast activation in OA mice. This invention demonstrates for the first time that isosakurabin has a therapeutic effect on osteoarthritis and reveals its mechanism of action.

The invention discloses application of chlorella in preparation of a medicine for treating osteoarthritis, in-vivo experiments and in-vitro experiments prove that chlorella can maintain a chondrocyte metabolism steady state, inhibit expression of chondrocyte extracellular matrix catabolism-related genes and proteins, and inhibit osteoarthritis. The expression of genes and proteins related to chondrocyte extracellular matrix anabolism is promoted, and by injecting a chlorella solution into a knee joint cavity, the effects of relieving and improving OA pain are achieved; furthermore, polydopamine is used for modifying the chlorella to obtain the polydopamine-coated chlorella Ch (at) P with a photothermal effect, and the Ch (at) P not only maintains the biological activity of the chlorella, but also has the effect of delaying cartilage degeneration and OA process due to the photothermal effect under near infrared (NIR) irradiation.

The application discloses a joint cavity filling preparation of precisely proportioned carboxymethyl chitosan and sodium glycerophosphate and a preparation method and application thereof, and the effective component of the filling preparation is carboxymethyl chitosan with a concentration of 25 mg / mL and sodium glycerophosphate with a concentration of 15 mg / mL, and the balance is a sterile isotonic physiological buffer aqueous solution. The application forms component synergy by relying on the lubrication and long-acting stability characteristics of carboxymethyl chitosan and combining the structure reinforcement, ion regulation and cartilage repair promoting characteristics of sodium glycerophosphate, and effectively solves the defects of short in-vivo retention time, poor mechanical stability, lack of biological repair activity and easy dilution and collapse of the traditional joint filling material in the joint cavity fluid. The application overcomes the problem that a high-concentration viscous solution cannot be filtered and sterilized, can effectively buffer the joint mechanical load, optimize the joint microenvironment and promote the repair of degenerative cartilage, is suitable for clinical scenes such as mild and moderate osteoarthritis, sports joint injury and postoperative joint function repair, and has good clinical application value and industrialization prospect.

The invention discloses an RIP3-mediated osteoarthritis animal model as well as a construction method and application thereof. The construction method comprises the following steps: delivering an effective dose of a genetic tool (such as an adenovirus vector) capable of expressing RIP3 protein into a knee joint subchondral bone area of an experimental animal, and realizing continuous overexpression of RIP3 through regular operation, so as to induce pathological characteristics highly similar to human osteoarthritis. The model stably shows typical OA phenotypes such as limb pain sensitization, subchondral bone loss and bone microstructure degeneration, osteoclast number increase and overlying cartilage degeneration. The invention reveals that the natural process of occurrence and development of the osteoarthritis can be directly simulated through specific overexpression of the RIP3 in the subchondral bone for the first time, and a brand-new and valuable tool is provided for researching the pathogenesis of the osteoarthritis and screening and evaluating medicines and therapies for treating the osteoarthritis.

The present invention relates to the field of nutraceuticals, specifically to a synergistic bioactive composition designed to improve joint health. This composition comprises Palmitoylethanolamide (PEA) and Cucumis sativus, aimed at reducing joint pain and protecting cartilage. It addresses the complex pain components of osteoarthritis, including both nociceptive pain, which stems from ongoing joint inflammation and tissue damage, and neuropathic pain, which indicates nerve damage. This nutraceutical composition provides a novel solution for mitigating the debilitating effects of osteoarthritis through oral administration, utilizing pharmaceutically acceptable excipients to ensure efficacy and safety.

The invention discloses an application of a cathepsin D inhibitor in preparation of a medicine for preventing or treating osteoarthritis, and an application of the cathepsin D inhibitor in preparation of a medicine for inhibiting degradation of type II collagen and / or articular cartilage. The invention relates to an application of a cathepsin D inhibitor in preparation of drugs for inhibiting expression of cathepsin D in bone joints. In the application, the cathepsin D can effectively relieve tissue lesions of osteoarthritis.

By using the helical axis in the knee joint movement of subjects during walking, we perform gait analysis that can be used to detect early-stage osteoarthritis of the knee. [Solution] A gait analysis method comprising the steps of: calculating the helical axis of the knee joint based on motion data of the subject's lower limbs during walking; extracting the flexion phase and extension phase during the stance phase of the subject's gait cycle; and obtaining an evaluation value to assess the condition of the knee by quantifying the variability of the helical axis group in one or both of the flexion phase and the extension phase.

The invention provides application of querceric acid in preparation of a medicine for improving osteoarthritis, and belongs to the technical field of medicines. The invention provides a novel application of the quercetin. The research finds that the quercetin can obviously reduce the joint diameter of a mouse with osteoarthritis, improve the joint swelling degree of the mouse with osteoarthritis, improve the joint movement function limitation degree of the mouse with osteoarthritis and effectively reduce the sensitivity of the mouse with osteoarthritis to nociceptive stimulation; the quercetin can also effectively improve liver and spleen pathological changes induced by MIA. The invention relates to an application of quercetin in preparation of a medicine for improving osteoarthritis.

The present invention provides compositions and methods for treating joint disorders that are characterized by an inflammatory component. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint.

The osteoarthritis self-adaptive load-bearing damping brace comprises a hook-and-loop fastener, a clamping and fixing unit capable of reducing the bending pressure of a knee joint is arranged on the back face of the hook-and-loop fastener, and a movable supporting unit for tightly attaching and protecting the knee joint is arranged on the side face of the clamping and fixing unit. The clamping and fixing unit comprises a movable middle shaft which is arranged on the side face of the hook-and-loop fastener and used for fixing different leg types; the two shells are placed at the bottoms of the thighs and the tops of the shanks of a user respectively, it is ensured that the two shells can be driven to be folded in the direction of the inclined supporting blocks when the legs are bent, at the moment, movable middle shafts are installed on the side faces of the shells, and it is ensured that push plates are tightly attached to the thigh peak of a patient; the binding band is installed in the side face of the shell, the movable middle shaft is bound to the legs of a user through cooperation of the binding band, the fixing buckle and the hook-and-loop fastener, at the moment, the movable clamping plate tightly wraps the legs of the user under the thrust of the movable middle shaft and the guide of the inclined face of the base plate, and the stability of the device in daily movement is guaranteed.

The invention belongs to the technical field of functional materials, and particularly relates to a preparation method and application of antioxidant carbon dots based on H2O2 diagnosis and treatment. According to the anti-oxidation carbon dot, curcumin and o-phenylenediamine serve as precursors, the anti-oxidation carbon dot with the fluorescence luminescence characteristic is prepared, and high-sensitivity response to H2O2 can be achieved. In an osteoarthritis environment, the carbon dot has a diagnosis and treatment effect by detecting H2O2 concentration change and using a fluorescence signal, and meanwhile, by virtue of the excellent oxidation resistance of the carbon dot, the progress of early joint diseases can be delayed. The carbon dots integrating detection and treatment functions have wide application prospects in the biomedical field, and particularly show important potential in diagnosis and treatment research of oxidative stress related diseases such as osteoarthritis.

Methods of use for treating osteoarthritis or vanishing bone disease in a subject in need, including methods of direct administration of a composition of early apoptotic cells or an apoptotic supernatant into or adjacent to the affected joint or bone tissue. Methods of use may reduce pain, swelling, inflammation, bone loss, and or cartilage degeneration, and may increase freedom of movement at an affected joint.

A method for treating joint pain in an individual chronically afflicted with osteoarthritis, the method comprising administering to the osteoarthritis individual repeat doses of a liposomal composition comprising an effective amount of an intra-articular corticosteroid or a pharmaceutically acceptable salt thereof, in an intra-articular administration manner. A robust and long-lasting intra-articular corticosteroid treatment efficacy response is achieved for more than one year, without any signs or symptoms of adrenal insufficiency in the individual.

The present invention relates to therapies for musculoskeletal conditions, and particularly although not exclusively, to therapies for treating conditions that affect the joints, such as osteoarthritis (OA) and rheumatoid arthritis.

A brace is provided, including a single upright assembly. The assembly includes an upper rigid support, lower rigid support, a hinge coupling the upper rigid support to the lower rigid support, an upper cuff coupled to the upper rigid support, and a lower cuff coupled to the lower rigid support. The brace includes a plurality of upper straps configured for coupling to the upper cuff such that the plurality of upper straps do not cross when the brace is properly attached to the subject. The brace includes a plurality of lower straps configured for coupling to the lower cuff such that the plurality of lower straps do not cross when the brace is properly attached to the subject. The brace includes a tensioning mechanism configured to adjust a tension in at least one of the plurality of upper and lower straps. Other braces and related methods are also provided.

A liposome encapsulating adenosine is provided herein. Liposomes can be formed by a combination of sphingomyelin or sphingomyelin and 1,2-dimyristoyl-sn-glycerol-3-phosphocholine (DMPC) or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycerol-3-phosphoglycerol (DMPG) or a combination of sphingomyelin, DMPG and DMPC. Liposomes encapsulating adenosine can be used to induce cartilage regeneration, treat osteoarthritis, relieve joint pain, and / or slow down, prevent and / or reverse the progressive structural tissue damage associated with osteoarthritis, or treat osteoarthritis, rheumatoid arthritis, acute gouty arthritis and / or synovitis. Liposomes can release adenosine for up to two weeks.